Large-Area Plasma Panel Detectors for Particle Beam Radiation Therapy

 描述(由申请人提供)：美国能源部和美国国家癌症研究所联合举办的离子束治疗研讨会(2013年1月，马里兰州贝塞斯达)确定了一系列雄心勃勃的技术开发，以支持世界级的离子束治疗计划。一个重要的要求是提供能够以高数据速率提供单粒子配准的探测器，具有HGH均匀程度和对粒子束的最小干扰。这将允许在治疗前执行质子或离子CT，并在治疗期间进行2D质子/离子射线照相，以进行综合射程验证，以及与主光束干扰最小的束流诊断。在质子成像系统的第一次开发中使用的当前硅探测器在最大可用探测器尺寸方面具有重大限制。目前使用的束流监测检测器也存在局限性，其不适合于粒子束扫描的未来临床应用所需的高束强度下的非常快的响应时间。我们建议开发一种新的探测器，等离子体面板传感器(Pps)，它有可能消除现有探测器的所有障碍，因此应该允许粒子束放射治疗充分发挥其在未来临床粒子束治疗中的潜力。 治疗中心。从根本上说，建议的探测器应该是本质上均匀的、低质量的、具有快速响应时间的。在第一阶段，我们成功地制造了超薄聚苯硫醚玻璃基板(即0.30、0.20和0.026 mm厚)，电极间距分别为2.54 mm和0.35 mm，对应的理论空间分辨率分别为~0.73 mm和0.10 mm，如Geant4蒙特卡罗模拟所示。因此，亚毫米图像分辨率似乎是完全可以实现的，当与潜在的高粒子检测效率相结合时，这些探测器可能成为粒子治疗治疗室成像和光束监控传感器的首选技术。在这项为期36个月的第二阶段SBIR中，我们建议：(1)在临床光束线上制造和测试一系列具有2D读出功能的超薄PPS设备，这些设备越来越大、分辨率越来越高；(2)开发探测器原型的Geant4蒙特卡罗模拟模型，以帮助数据分析、设备设计改进和性能优化；以及(3)证明超薄PPS设备将满足我们第一阶段最终报告中总结的临床要求。达到SBIR第二阶段的目标将使集成传感器能够产生第三阶段的资金，以生产一种通用探测器系统，该系统将提高质子和离子粒子束治疗的疗效和安全性。

 DESCRIPTION (provided by applicant): A joint DOE-NCI workshop on ion beam therapy (January 2013, Bethesda, MD) identified an ambitious set of technology developments needed to support a world-class treatment program for ion beam therapy. One important requirement is the ability to provide detectors that afford single-particle registration at high data rates with hgh degree of uniformity and minimal interference with the particle beam. This would allow performing proton or ion CT prior to treatment and 2D proton/ion radiography during treatment for integrated range verification, along with beam diagnostics that have minimal interference with the primary beam. Current silicon detectors employed in first developments of proton imaging systems have major limitations in terms of maximum available detector size. Limitations also exist for currently used beam monitoring detectors that are not suitable for very fast response times at high beam intensities required for future clinical applications of particle beam scanning. We propose to develop a novel detector, the plasma panel sensor (PPS), that has the potential to remove all the barriers of existing detectors and should therefore allow particle beam radiation therapy to realize its fullest potential to be used in future clinical particle beam therapy centers. Fundamentally the proposed detectors should be inherently uniform and of low mass with fast response time. During Phase I we were successful manufacturing ultrathin-PPS glass substrates (i.e., 0.30, 0.20 and 0.026 mm thickness) with electrode pitches of 2.54 mm and 0.35 mm, corresponding to theoretical spatial resolutions of ~ 0.73 mm and 0.10 mm, respectively, as demonstrated with Geant4 Monte Carlo simulations. Sub-millimeter image resolution thus seems eminently achievable, and when combined with potentially high particle detection efficiencies could make these detectors the technology of choice for both imaging and beam monitoring sensors in the particle therapy treatment room. In this 36-month Phase II SBIR we propose to: (1) fabricate and test on a clinical beam line a series of progressively larger and higher resolution, ultrathin-PPS devices with 2D readout; (2) develop Geant4 Monte Carlo simulation models of the detector prototypes to assist in data analysis, device design refinement, and performance optimization; and (3) demonstrate that the ultrathin-PPS devices will meet the clinical requirements as summarized in our Phase-I Final Report. Meeting the target objectives of this SBIR Phase II will enable Integrated Sensors to generate the Phase III funds to produce a universal detector system that will improve both treatment efficacy and the safety of particle beam therapy with protons and ions.